RxDoctor Payments Data

Samantha Schroeder, APRN

Family · Covington, LANPI 1851986046

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 35 payments — averaging $36.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$177
  • AstraZeneca$134
  • Sanofi$125
  • Exelixis Inc.$122
  • E.r. Squibb & Sons, L.L.C.$117
  • AbbVie$92
  • plus $508 from 15 others

What the payments were for

  • Food & beverage$1,09886%
  • Education$17714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 65th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,393
Medicare patients
24
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$28,915
TrulicityDulaglutide18$24,492
JardianceEmpagliflozin39$24,348
MounjaroTirzepatide20$21,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,140
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$2,167
Clonidine21$2,155
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,873
Albuterol Sulfate HfaAlbuterol Sulfate53$1,434
Gabapentin90$1,223
Atorvastatin Calcium121$1,090
Esomeprazole Magnesium15$1,013
Duloxetine Hcl20$778
Levothyroxine Sodium70$707
Losartan Potassium67$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$44$46,43651 claims
Novo NordiskOzempic$36$28,91531 claims
GSKTrelegy Ellipta$39$7,14012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,610 family providers in Louisiana.

Other family in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →